# Malic enzyme 2 suppresses PINK1-Parkin-mediated mitophagy by stabilizing ATAD3A via competitive interaction with TRIM25

**Authors:** Qian Liu, Lei Su, Xiaoyun Wei, Shijie Lin, Lingkai Huang, Lige Hou, Yanhong Wang, Liubing Hu, Junyang Tan, Jing Qiao, Qinghua Zhou, Yi Ma, Wenjun Wang, Jianshuang Li

PMC · DOI: 10.1038/s41419-026-08623-2 · Cell Death & Disease · 2026-03-24

## TL;DR

Malic enzyme 2 suppresses mitophagy by stabilizing ATAD3A, and its depletion enhances mitophagy, affecting mitochondrial health and cell proliferation.

## Contribution

This study reveals a novel regulatory mechanism of mitophagy involving malic enzyme 2, TRIM25, and ATAD3A.

## Key findings

- ME2 depletion enhances PINK1-Parkin-mediated mitophagy by disrupting TRIM25-ATAD3A binding.
- Loss of ME2 leads to ATAD3A ubiquitination and degradation, increasing PINK1 levels and mitophagy activation.
- Pharmacological inhibition of mitophagy rescues cell proliferation in ME2-knockdown hepatoma cells.

## Abstract

Malic enzyme 2 (ME2), a pivotal enzyme related to the tricarboxylic acid (TCA) cycle, has been implicated in multiple cancers due to its overexpression and metabolic role in regulating the NADP+/NADPH balance. Malic enzyme 2 has been reported to regulate mitochondrial biogenesis and fusion; however, whether malic enzyme 2 participates in mitophagy regulation has remained unclear. Here, we reported that malic enzyme 2 depletion enhances PINK1-Parkin-mediated mitophagy. Mechanistically, ME2 competes with the E3 ubiquitin ligase TRIM25, disrupting its binding with ATPase family AAA domain-containing protein 3 A (ATAD3A), a mitochondrial protein crucial for the degradation of PINK1. Loss of malic enzyme 2 strengthens the TRIM25-ATAD3A interaction, resulting in ATAD3A ubiquitination and proteasomal degradation. The consequent PINK1 accumulation drives mitophagy activation. Hyperactivated mitophagy caused by malic enzyme 2 knockdown disrupts mitochondrial homeostasis, which suppresses the proliferative capacity of hepatoma cells. Moreover, pharmacological inhibition of mitophagy partially rescued the suppressed cell proliferation in the malic enzyme 2-knockdown cells. Our findings reveal a previously unrecognized role of malic enzyme 2 in mitochondrial quality control and highlight the ME2-ATAD3A-PINK1 axis as a potential regulatory node for mitophagy modulation.

## Linked entities

- **Genes:** ME2 (malic enzyme 2) [NCBI Gene 4200], TRIM25 (tripartite motif containing 25) [NCBI Gene 7706], ATAD3A (ATPase family AAA domain containing 3A) [NCBI Gene 55210], PINK1 (PTEN induced kinase 1) [NCBI Gene 65018]
- **Proteins:** TRIM25 (tripartite motif containing 25), ATAD3A (ATPase family AAA domain containing 3A), PINK1 (PTEN induced kinase 1)
- **Diseases:** hepatoma (MONDO:0007256)

## Full-text entities

- **Genes:** ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, TOMM70 (translocase of outer mitochondrial membrane 70) [NCBI Gene 9868] {aka TOMM70A, Tom70}, TOMM22 (translocase of outer mitochondrial membrane 22) [NCBI Gene 56993] {aka 1C9-2, MST065, MSTP065, TOM22}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, DUT (deoxyuridine triphosphatase) [NCBI Gene 1854] {aka BMFDMS, dUTPase}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, ME2 (malic enzyme 2) [NCBI Gene 4200] {aka ODS1}, TIMM23 (translocase of inner mitochondrial membrane 23) [NCBI Gene 100287932] {aka TIM23}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, HSPD1 (heat shock protein family D (Hsp60) member 1) [NCBI Gene 3329] {aka CPN60, GROEL, HLD4, HSP-60, HSP60, HSP65}, ULK1 (unc-51 like autophagy activating kinase 1) [NCBI Gene 8408] {aka ATG1, ATG1A, UNC51, Unc51.1, hATG1}, TOMM20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 9804] {aka MAS20, MOM19, TOM20}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, TRIM25 (tripartite motif containing 25) [NCBI Gene 7706] {aka EFP, RNF147, Z147, ZNF147}, ATAD3A (ATPase family AAA domain containing 3A) [NCBI Gene 55210] {aka HAYOS, PHRINL}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, TOMM40 (translocase of outer mitochondrial membrane 40) [NCBI Gene 10452] {aka C19orf1, D19S1177E, PER-EC1, PEREC1, TOM40}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}
- **Diseases:** mitochondrial morphological abnormalities (MESH:D000013), inflammatory (MESH:D007249), breast cancer (MESH:D001943), cancer (MESH:D009369), B cell lymphopenia (MESH:D015448), erythroid anemia (MESH:D029503), neurodegenerative diseases (MESH:D019636), mitochondrial damage (MESH:D028361), deficiency (MESH:D007153), colorectal cancer (MESH:D015179), HCC (MESH:D006528), spondyloarthritis (MESH:D013167), lung cancer (MESH:D008175), metastasis (MESH:D009362), acute myeloid leukemia (MESH:D015470)
- **Chemicals:** NaCl (MESH:D012965), puromycin (MESH:D011691), glucose (MESH:D005947), melatonin (MESH:D008550), polyacrylamide (MESH:C016679), antimycin A (MESH:D000968), malate (MESH:C030298), ATP (MESH:D000255), CO2 (MESH:D002245), digitonin (MESH:D004072), CQ (MESH:D002738), pyruvate (MESH:D019289), PBS (MESH:D007854), amino acid (MESH:D000596), BafA1 (MESH:C040929), penicillin (MESH:D010406), CCCP (MESH:D002258), ROS (MESH:D017382), FCCP (MESH:D002259), succinic acid (MESH:D019802), lipid (MESH:D008055), rotenone (MESH:D012402), NADP+ (MESH:D009249), oligomycin (MESH:D009840), fumarate (MESH:D005650), EDTA (MESH:D004492), PEI (MESH:D011094), MG132 (MESH:C072553), SDS (MESH:D012967), DAPI (MESH:C007293), paraformaldehyde (MESH:C003043), L-glutamine (MESH:D005973), Mdivi-1 (MESH:C000723896), lactate (MESH:D019344), NP-40 (MESH:C010615), TCA (MESH:D014233), Oxygen (MESH:D010100), Triton X-100 (MESH:D017830), crystal violet (MESH:D005840), Dulbecco's Modified Eagle Medium (-), polybrene (MESH:D006583), cholesterol (MESH:D002784), PVDF (MESH:C024865), streptomycin (MESH:D013307)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** Y112A, R67Q, K183A
- **Cell lines:** SCSP-502 — Homo sapiens (Human), Tay-Sachs disease, Finite cell line (CVCL_U382), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), pLKO.1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039799/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039799/full.md

---
Source: https://tomesphere.com/paper/PMC13039799